Healthcare Industry News: p53
News Release - June 16, 2008
IRX Therapeutics Names Scott M. Freeman, M.D. Chief Operating OfficerNEW YORK--(HSMN NewsFeed)--IRX Therapeutics, a privately-held company dedicated to the discovery and development of proprietary drugs for the treatment of cancer and viral diseases, today announced the appointment of Scott M. Freeman, M.D. as Chief Operating Officer. He has been a Senior Medical Advisor to IRX since 2007.
Prior to joining IRX, Dr. Freeman served as Vice President of Clinical Development at Onyx Pharmaceutical from 2001 to 2006 where he oversaw the head and neck as well as renal cell, melanoma, and colorectal cancer clinical trials and successfully ran Phase 1, 2, and 3 studies. He was a key leader in the clinical development and regulatory strategy which lead to FDA approval of Nexavar for kidney and liver cancer. From 1998 to 2001, he held the title of Clinical Project Director at Schering-Plough Research Institute where his clinical projects included an anti-estrogen program, a breast cancer treatment, and a p53 gene therapy program trial. From 1992 to 1998, Dr. Freeman held the position of Associate Professor at Tulane University where he also served as the Medical Director of the Blood Center. He was also an Adjunct Associate Professor at the University of Rochester from 1992 to 1998.
Dr. Freeman has been published in a book and sixty-four publications, developed four clinical protocols, and holds two patents. In 1978, Dr. Freeman earned his BA from the University of Colorado and received his MD from the University of Nevada in 1983. Dr. Freeman completed an internship at the University of Minnesota where he also completed his residency in clinical pathology.
“Dr. Freeman has been a valued part of our team for over a year and has earned our trust and respect,” said John W. Hadden II, President & Chief Executive Officer. “We look forward to his contribution in his expanded role as we move into the global Phase 3 clinical trial of our lead product candidate, IRX-2.”
About IRX Therapeutics
IRX Therapeutics is a privately-held immunotherapy company founded by John W. Hadden, M.D., a pioneer in the field of Immunopharmacology. The Company’s product platform seeks to restore an effective cellular immune response for the treatment of advanced cancers and viral diseases by correcting both dendritic cell and T-cell defects. An effective immune response is essential for the eradication of viruses and tumors.
The Company’s lead product, IRX-2 (citoplurikin), received Fast Track designation by the Food and Drug Administration. Phase 1/2 and Phase 2 clinical trials in late-stage head and neck cancer patients have been completed.
For more information on IRX Therapeutics, please visit the Company’s website at http://www.irxtherapeutics.com.
Source: IRX Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.